GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (LSE:SHP) » Definitions » Cash Payments for Loans

Shire (LSE:SHP) Cash Payments for Loans


View and export this data going back to 1996. Start your Free Trial

What is Shire Cash Payments for Loans?

Cash Payments for Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Shire (LSE:SHP) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.